JNJ 61393215

Drug Profile

JNJ 61393215

Alternative Names: JNJ-61393215

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Janssen-Cilag
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Unspecified

Most Recent Events

  • 30 Dec 2016 Janssen Research & Development plans a phase I trial (In volunteers) in Netherlands (NCT03007693)
  • 01 Nov 2016 Janssen-Cilag International completes enrolment in its phase I trial (In volunteers) in Netherlands (NCT02812251)
  • 01 Jul 2016 Phase-I clinical trials in Undefined indication (In volunteers) in Netherlands (PO) (NCT02812251)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top